AIM: To test for association of SLC11A1 with inflammatory bowel disease (IBD) and Mycobacterium avium subspecies paratuberculosis (MAP) status in a Caucasian cohort. METHODS: five hundred and seven Crohn's disease (CD) patients, 474 ulcerative colitis (UC) patients, and 569 healthy controls were genotyped for SLC11A1 1730G>A and SLC11A1 469+14G>C using pre-designed TaqMan SNP assays. χ(2) tests were applied to test for association of single nucleotide polymorphisms (SNPs) with disease, and the presence of MAP DNA. RESULTS: SLC11A1 1730G>A and SLC11A 1469+14G>C were not associated with CD, UC, or IBD. The SLC11A1 1730A minor allele was over-represented in patients who did not require immunomodulator therapy (P = 0.002, OR: 0.29, 95% CI: 0.13-0.66). The frequency of the SLC11A1 469+14C allele was higher in the subset of study participants who tested positive for MAP DNA (P = 0.02, OR: 1.56, 95% CI: 1.06-2.29). No association of SLC11A1 1730G>A with MAP was observed. CONCLUSION: Although SLC11A1 was not associated with IBD, association with MAP suggests that SLC11A1 is important in determining susceptibility to bacteria implicated in the etiology of CD.
AIM: To test for association of SLC11A1 with inflammatory bowel disease (IBD) and Mycobacterium avium subspecies paratuberculosis (MAP) status in a Caucasian cohort. METHODS: five hundred and seven Crohn's disease (CD) patients, 474 ulcerative colitis (UC) patients, and 569 healthy controls were genotyped for SLC11A1 1730G>A and SLC11A1 469+14G>C using pre-designed TaqMan SNP assays. χ(2) tests were applied to test for association of single nucleotide polymorphisms (SNPs) with disease, and the presence of MAP DNA. RESULTS:SLC11A1 1730G>A and SLC11A 1469+14G>C were not associated with CD, UC, or IBD. The SLC11A1 1730A minor allele was over-represented in patients who did not require immunomodulator therapy (P = 0.002, OR: 0.29, 95% CI: 0.13-0.66). The frequency of the SLC11A1 469+14C allele was higher in the subset of study participants who tested positive for MAP DNA (P = 0.02, OR: 1.56, 95% CI: 1.06-2.29). No association of SLC11A1 1730G>A with MAP was observed. CONCLUSION: Although SLC11A1 was not associated with IBD, association with MAP suggests that SLC11A1 is important in determining susceptibility to bacteria implicated in the etiology of CD.
Authors: M J Kotze; J N de Villiers; R N Rooney; J J Grobbelaar; E P Mansvelt; C S Bouwens; J Carr; I Stander; L du Plessis Journal: Blood Cells Mol Dis Date: 2001 Jan-Feb Impact factor: 3.039
Authors: O Ates; L Dalyan; B Müsellim; G Hatemi; H Türker; G Ongen; V Hamuryudan; A Topal-Sarikaya Journal: Int J Immunogenet Date: 2008-11-25 Impact factor: 1.466
Authors: J Liu; T M Fujiwara; N T Buu; F O Sánchez; M Cellier; A J Paradis; D Frappier; E Skamene; P Gros; K Morgan Journal: Am J Hum Genet Date: 1995-04 Impact factor: 11.025
Authors: M Cellier; G Govoni; S Vidal; T Kwan; N Groulx; J Liu; F Sanchez; E Skamene; E Schurr; P Gros Journal: J Exp Med Date: 1994-11-01 Impact factor: 14.307
Authors: B Gopi; Ran Vir Singh; Satish Kumar; Sushil Kumar; Anuj Chauhan; Arvind Sonwane; Amit Kumar; Jaya Bharati; Shoor Vir Singh Journal: Vet Res Commun Date: 2021-10-30 Impact factor: 2.459